Infinity Pharmaceuticals Profit Margin

Infinity Pharmaceuticals (INFI) currently reports a profit margin of -1577.7% as of June 2023. That compares with -2110.33% in the prior-year period — up 25.2% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Infinity Pharmaceuticals's profit margin history and peer comparisons.

Infinity Pharmaceuticals's profit margin increased from -2110.33% to -1577.7% — a 25.2% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Infinity Pharmaceuticals's profit margin of -1577.7% is lower than the Healthcare sector average of 13.89%. That is roughly 11456.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Infinity Pharmaceuticals's current -1577.7% should be judged against Healthcare norms (sector average: 13.89%) and against INFI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1577.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Infinity Pharmaceuticals, and consider following INFI for alerts when major investors trade the stock.